Naftifine Hcl (naftifine HCl)

For the treatment of tinea cruris, tinea corporis, or tinea pedis, a sufficient amount of naftifine hydrochloride topical cream or gel should be applied and rubbed gently into the affected and surrounding skin areas; naftifine hydrochloride topical cream should be applied once daily and naftifine hydrochloride topical gel should be applied twice daily, in the morning and evening.

Clinical improvement usually occurs within the first week of treatment with naftifine hydrochloride topical cream. Tinea cruris and tinea corporis generally are treated for 2-4 weeks and tinea pedis for 4-6 weeks; severe infections may require more prolonged therapy. If clinical improvement does not occur after 4 weeks of treatment with naftifine hydrochloride topical cream or gel, the diagnosis should be reevaluated.

Naftifine hydrochloride is applied topically to the skin as a 1% cream or gel. The cream or gel should not be applied to the eye, and contact with the nose, mouth, and other mucous membranes should be avoided. Occlusive dressings or wrappings should not be used, and hands should be washed after applying the cream.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• No disease contraindications

There is no enhanced messaging for this drug.

Rare or Very Rare

• Agranulocytosis
• Leukopenia

More Frequent

• Pruritus of skin
• Skin irritation
• Stinging of skin

Rare or Very Rare

• Blistering skin
• Dizziness
• Erythema
• Headache disorder
• Skin crusting
• Skin inflammation
• Skin rash
• Skin swelling

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in rats and rabbits using oral naftifine hydrochloride in doses 150 or more times the usual topical human dose have not revealed evidence of harm to the fetus. In in vitro studies using rat embryos exposed to the drug, there was no evidence of embryotoxicity at concentrations of 10 mcg/mL or less; however, adverse effects on embryonic growth and differentiation and morphologic abnormalities of a nonspecific pattern did occur at concentrations of 30 mcg/mL or greater. There are no adequate and controlled studies to date using topical naftifine in pregnant women, and the drug should be used during pregnancy only when clearly needed.

Although naftifine is distributed into the milk of rats, it is not known whether the drug is distributed into human milk. The manufacturer states that topical naftifine should be used with caution in nursing women; however, it is unlikely that clinically important concentrations of naftifine could be achieved in breast milk following topical application of usual dosages to the skin.

No enhanced messaging available.